Type 2 Diabetes News and Research

Latest Type 2 Diabetes News and Research

Takeda underscores commitment to ACTOS following FDA and EMA announcements for rosiglitazone

Following today’s announcements by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for rosiglitazone in the U.S. and Europe, Takeda Pharmaceuticals North America, Inc. and Takeda Pharmaceuticals Europe Limited underscore the company’s commitment to ACTOS® (pioglitazone HCl) and ACTOS-containing medications, and to the millions of people living with type 2 diabetes.

24 Sep 2010

EMA, FDA announce regulatory decisions on Avandia drug

GlaxoSmithKline confirms that following a review of Avandia (rosiglitazone maleate) by the European Medicines Agency (EMA) and the US Food and Drug Administration (FDA), each agency has today announced their individual regulatory decisions and the resulting actions.

24 Sep 2010

Albert Einstein College researchers to hold congressional briefing on global diabetes epidemic

On Monday, September 27, researchers from Albert Einstein College of Medicine of Yeshiva University will hold a congressional briefing in Washington, D.C., aimed at focusing attention on the alarming global diabetes epidemic.

24 Sep 2010

Avandia restricted by the FDA and EMEA

The U.S. Food and Drugs Administration (FDA) has restricted the use of the controversial diabetes drug Avandia (rosiglitazone) due to its propensity to increase cardiovascular disease risk.

24 Sep 2010

Abbott, Reata enter agreement to commercialize bardoxolone drug for CKD

Abbott and Reata Pharmaceuticals today announced that they have entered into a collaboration agreement to develop and commercialize bardoxolone methyl (bardoxolone), which is currently in late Phase 2 trials for the treatment of chronic kidney disease (CKD).

24 Sep 2010

Type 1 diabetes, early recognition, telltale signs

Though they may present in a similar fashion, type 1 diabetes mellitus is vastly different from type 2, and Ralph Schmeltz, MD, incoming president of the Pennsylvania Medical Society, says it’s important to recognize and diagnose it early.

23 Sep 2010

Study reveals elevated risk of type 2 diabetes in South Asians than other Asian immigrants

South Asians living in the United States are at much higher risk for type 2 diabetes than are whites and immigrants from other Asian countries, a new small study reveals.

23 Sep 2010

Tolerx presents otelixizumab preclinical research at 46th EASD

Tolerx, Inc., a biopharmaceutical company developing novel therapies to treat autoimmune diseases and cancer by modulating T cell activity, today announced the presentation of preclinical research describing the mechanism of action of otelixizumab at the 46th Annual Meeting of the European Association for the Study of Diabetes (EASD). In addition, Tolerx also announced that the first European patient was enrolled in DEFEND-2, a confirmatory Phase 3 clinical trial evaluating otelixizumab in autoimmune new-onset type 1 diabetes.

23 Sep 2010

Linagliptin clinical trial data shows positive result for type 2 diabetes treatment

New data from the linagliptin late stage clinical trial programme were presented this week at the 46th Annual Meeting of the European Association for the Study of Diabetes (EASD).

23 Sep 2010

Over one in three diabetics do not take insulin as prescribed

More than one in three diabetes patients skip doses or fail to take their insulin as prescribed, stating that they have done so on average three times in the last month, and 77 percent of physicians estimate that in reality this number could be as high as six doses, according to the Global Attitudes of Patients and Physicians in Insulin Therapy (GAPP™) survey, released today by Novo Nordisk.

23 Sep 2010

Women who smoke during pregnancy can harm child's motor ability: Study

Women who smoke during pregnancy run the risk of adversely affecting their children's coordination and physical control according to a new study from rebro University, Sweden, published in the Journal of Epidemiology and Community Health.

23 Sep 2010

Intarcia Therapeutics presents ITCA 650 phase 2 study results for type 2 diabetes

Intarcia Therapeutics, Inc. presented today final results of a 24-week phase 2 clinical study of ITCA 650 (DUROS continuous subcutaneous delivery of exenatide) for the treatment of type 2 diabetes at the 46th Annual Meeting of the European Association for the Study of Diabetes in Stockholm, Sweden.

23 Sep 2010

Boehringer Ingelheim to present linagliptin Phase III data at 46th EASD

New Phase III data found that investigational linagliptin therapy resulted in significant reductions in blood sugar as measured by hemoglobin A1c (HbA1c) when compared to placebo, both when added to sulfonylurea (SU) in inadequately controlled type 2 diabetes (T2D) patients, and when administered as monotherapy in T2D patients for whom metformin is inappropriate.

22 Sep 2010

Smoking during pregnancy adversely affects children's coordination and physical control

Women who smoke during pregnancy run the risk of adversely affecting their children's coordination and physical control according to a new study from örebro University, Sweden, published in the Journal of Epidemiology and Community Health.

22 Sep 2010

Some insurers to end child-only policies rather than comply with health law

Major insurers plan to discontinue child-only health plans rather than issue coverage under such plans for children with preexisting conditions, something they would have to do beginning Sept. 23 as part of the health law, The Washington Post reports. WellPoint, Cigna and CoventryOne are among the insurers that will end the plans. Those children already covered under the plans would be able to continue, and the companies "will accept children with preexisting conditions in new family policies" (Aizenman, 9/20).

22 Sep 2010

ChemoCentryx presents CCX140 clinical data at EASD

ChemoCentryx, Inc., today announced that it reported positive preclinical and Phase I study results at the European Association for the Study of Diabetes (EASD). CCX140, a novel, orally bioavailable small molecule antagonist of the chemokine receptor CCR2, improved metabolic function while significantly reducing inflammatory macrophages found in adipose tissue in an animal model, and was well tolerated in Phase I clinical trials.

21 Sep 2010

VIVUS announces QNEXA study results for obesity treatment

VIVUS, Inc. today announced positive top-line results from a two-year study of QNEXA(phentermine/topiramate) Controlled Release Capsules, an investigational therapy for treatment of obesity, a condition that affects approximately one-third of adult Americans.

21 Sep 2010

New professional handbook highlights fast-growing trends in scientific knowledge

As genomic advances reveal new insights into what underlies human health and disease, important questions emerge about the meaning of this information for entire families especially children and their parents. Now, a new professional handbook is available to help researchers, practitioners, and policy makers understand the impacts of these discoveries on child and family well-being.

21 Sep 2010

Lixisenatide experimental diabetes drug shows potential in trial

Researchers at the R&D section of drug maker Sanofi Aventis have confirmed this Monday that a study of its experimental diabetes drug showed better blood sugar control than placebo.

21 Sep 2010

Biomarkers may help predict children at high risk of developing type 2 diabetes

Children who have a high risk of developing type 2 diabetes might be identified earlier by way of tell-tale genetic indicators known as biomarkers. Some of those new biomarkers might be pinpointed in research led by Nancy F. Butte and funded by the U.S. Department of Agriculture (USDA) and the U.S. Department of Health and Human Service's National Institutes of Health.

20 Sep 2010